Stocks and Investing Stocks and Investing
Fri, October 15, 2021

Paul Matteis Maintained (BIIB) at Strong Buy with Decreased Target to $344 on, Oct 15th, 2021


Published on 2024-10-27 18:10:26 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Maintained "Biogen Inc." (BIIB) at Strong Buy with Decreased Target from $430 to $344 on, Oct 15th, 2021.

Paul has made no other calls on BIIB in the last 4 months.



There are 9 other peers that have a rating on BIIB. Out of the 9 peers that are also analyzing BIIB, 3 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $290 on, Friday, October 8th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $326 on, Wednesday, September 29th, 2021
  • Salim Syed of "Mizuho" Maintained at Hold with Increased Target to $300 on, Monday, August 2nd, 2021


These are the ratings of the 6 analyists that currently disagree with Paul


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $447 on, Tuesday, October 12th, 2021
  • Michael Yee of "Jefferies" Maintained at Strong Buy with Decreased Target to $400 on, Friday, October 8th, 2021
  • Ami Fadia of "Needham" Initiated at Strong Buy and Held Target at $400 on, Thursday, September 23rd, 2021
  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $442 on, Thursday, September 16th, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $423 on, Tuesday, July 27th, 2021
  • Christopher Raymond of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $450 on, Friday, June 18th, 2021

Contributing Sources